Discover Grünenthal

2/24/2025

Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.

Florian Dieckmann, Head Global Corporate Affairs & Communication

Florian Dieckmann

Head Global Corporate Affairs & Communication


Grünenthal GmbH

52099 Aachen


Phone +49 241 569 2555

E-Mail Florian.Dieckmann@grunenthal.com